Human Microbiome Market

The Human Microbiome market is expected to reach USD 4,206.0 million in 2030 from USD 814.6 million in 2024, at a CAGR of 31.5% during the forecast period. The major factors driving the growth of the human microbiome market are the advancements in microbiome sequencing, Improved sequencing methods enable precise analysis of microbiome composition and dynamics, which stimulates research, attracts investment, and accelerates the development of microbiome-based products, expanding market opportunities and application. These advancement have given rise to a whole new segment in the form of microbiome sequencing industry and other supportive adjacent companies improving the development of microbiome biome based therapies. Increase in demand for personalized services is another factor that is expected to drive growth in this market.

The human microbiome market is a dynamic market wherein, microbiome drugs market space is consolidated with currently only two drugs approved in US for the prevention of C. difficile infection, VOWST (Seres Therapeutics) and Rebyota (Ferring Pharmaceuticals). Collectively, the human microbiome (drugs, probiotics, prebiotics, and synbiotics) market is consolidated, with the top players like Seed Health, Inc. (US), International Flavors & Fragrances, Inc. (US), Seres Therapeutics, Inc (US), Ferring Pharmaceuticals (Switzerland), and Pendulum (US). The market players have adopted various strategies such as new product launches, acquisitions, agreements, partnerships, and geographical expansions to strengthen their position in the human microbiome market.

To know about the assumptions considered for the study download the pdf brochure

Seres Therapeutics, Inc. (US)

Seres Therapeutics is one of the emerging players in the human microbiome market. The company’s microbiome therapeutics platform significantly reduces the time typically required to advance therapeutics to the clinic and, ultimately, to the market. The company focuses on R&D to launch advanced products in the market. Its R&D expenses were USD 145 Million for the year ended December 31, 2023. Seres Therapeutics has collaborated with various companies like Nestlé and Bacthera as their products advance clinical development, re-evaluate the clinical development of SER-287, and evaluate the potential to utilize biomarker-based patient selection and stratification in future clinical development efforts.

Ferring Pharmaceuticals (Switzerland)

Ferring Pharmaceutical’s revenue has seen a growth, owing to Ferring being the first company to receive approval for their fecal microbiota transplant product in the US which rendered them a key player in the human microbiome market space. They have emerged as a leading player through a combination of Organic and inorganic growth strategies bolstered by Regulatory approvals, Product Launches, Collaborations, and Strong R&D. Their collaboration with PharmaBiome (Switzerland) in December 2023 is indicative of their commitment to develop and innovate in Human Microbiome Space.

Seed Health, Inc. (US)

Seed Health offers unique products such as Synbiotics in their portfolio which makes them stand out from the herd. Apart from their product offerings seed health also has various collaborations such as their collaboration with the Swiss Institute of Allergy and Asthama Research (SAIF) which enabled them to launch their Platform to develop next-generation human microbiome products, agreements and several products in pre-clinical phases which makes them a leader in Human Microbiome Market. This is further emphasized from their acquisition of augGI Technologies, Inc.(US) which is a digital health company with a suite of artificial intelligence and machine learning technologies to track and analyze digestive health. Seed Health Inc. aims to utilize their technology to improve adherence and outcomes in their products. Hence this instances also showcases Seed Health’s vision for future by utilizing AI and machine learning technologies to further develop the next generation of synbiotics and probiotics.

Related Reports:

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics, Synbiotics), Diseases (Infectious, Gastrointestinal, Endocrine & Metabolic), Type (BCT/FMT, Live Biotherapeutics), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]